XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborations with Third Parties (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 26, 2021
Apr. 17, 2020
Jan. 02, 2019
May 31, 2021
Dec. 31, 2020
Jun. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Collaborations with Third Parties                    
Collaboration revenue             $ 14,409,000 $ 3,833,000 $ 63,046,000 $ 217,909,000
Collaboration revenue                    
Collaborations with Third Parties                    
Collaboration revenue             3,514,000 502,000 35,191,000 213,111,000
Daiichi Sankyo Europe GmbH ("DSE") | Regulatory performance obligations                    
Collaborations with Third Parties                    
Upfront payment, revenue recognized                   1,600,000
Daiichi Sankyo Europe GmbH ("DSE") | Royalty revenue and product sales bulk tablets                    
Collaborations with Third Parties                    
Collaboration revenue             3,300,000 $ 500,000 6,900,000 1,500,000
Daiichi Sankyo Europe GmbH ("DSE") | NUSTENDI, MAA                    
Collaborations with Third Parties                    
Collaboration revenue                   150,000,000
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement                    
Collaborations with Third Parties                    
Upfront cash payment received (paid)     $ 150,000,000              
Cash payment to the Company upon first commercial sales in the DSE Territory     $ 150,000,000              
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales     15.00%              
Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales     25.00%              
Daiichi Sankyo Europe GmbH ("DSE") | Amended License and Collaboration Agreement                    
Collaborations with Third Parties                    
Proceeds received upon completion of NUSTENDI MAA transfer           $ 150,000,000        
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities                    
Collaborations with Third Parties                    
Upfront cash payment received (paid)   $ 60,000,000                
Potential additional future payments   $ 450,000,000                
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Collaboration revenue                    
Collaborations with Third Parties                    
Collaboration revenue             0   0 $ 60,000,000
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales   15.00%                
Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales   30.00%                
Milestone payment, first JNDA submissions   $ 20,000,000                
Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory   70,000,000                
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label   50,000,000                
Milestone payments related to total net sales achievements   $ 310,000,000                
Daiichi Sankyo Co. Ltd                    
Collaborations with Third Parties                    
Collaboration revenue                 28,300,000  
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement                    
Collaborations with Third Parties                    
Upfront cash payment received (paid)       $ 30,000,000            
Collaboration revenue             $ 200,000   28,300,000  
Potential additional future payments $ 175,000,000                  
Future upfront payment 30,000,000                  
Cash payment to be received upon certain commercial milestones $ 175,000,000                  
Deferred up-front payment                 1,700,000  
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Minimum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales 5.00%                  
Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Maximum                    
Collaborations with Third Parties                    
Percentage of royalties to be received on the net sales 20.00%                  
Daiichi Sankyo Co. Ltd | Collaborative Arrangement, License To Intellectual Property                    
Collaborations with Third Parties                    
Collaboration revenue                 28,000,000  
Daiichi Sankyo Co. Ltd | Collaborative Arrangement, Ongoing Regulatory And Development Activities                    
Collaborations with Third Parties                    
Collaboration revenue                 $ 300,000  
Serometrix | License and Collaboration Agreement                    
Collaborations with Third Parties                    
Upfront cash payment received (paid)         $ 12,500,000